← Back to Patent Explorer
US4048307A Expired / Lapsed US ⏱️ 0.0 years remaining

Cyclic adenosine monophosphate 8-substituted derivatives

Assignee: Asahi Kasei Corp
•
Filing: 1975-09-24
•
Granted: 1977-09-13
•
Expires: 1995-09-24
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Novel cyclic adenosine monophosphate derivatives represented by the following general formula: ##STR1## wherein A stands for --S-- or --NH-- and n is an integer of from 2 to 12, ARE SUPERIOR TO KNOWN CYCLIC ADENOSIENE DERIVATIVES IN BIOLOGICAL AND PHARMACOLOGICAL ACTIVITIES, ESPECIALLY PDE-inhibiting activity and membrane permeability. Accordingly, these derivatives are very effective for remedying and controlling diseases caused by disorder of the intracellular cyclic adenosine monophosphate level, such as asthma and scabies. These derivaives can readily be synthesized by reacting an 8-halogeno cyclic adenosine monophosphate of the following general formula ##STR2## wherein X is a halogen atom such as bromine, with an alkali metal salt of a linear alkylmercaptan having 3 to 13 carbon atoms in the alkyl group or a linear alkylamine having 3 to 13 carbon atoms in the alkyl group.

Inventors

  • 👤 Takeshi Yokota
  • 👤 Nobuyuki Suzuki
  • 👤 Tsuneo Sowa
  • 👤 Yasuharu Sasaki
  • 👤 Yasutaka Ono

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 17:33
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/16; C07H19/20

Claims Analysis

Total Claims: 38
Claim 1
Independent Claim 35 words
A cyclic adenosine monophosphate represented by the formula, or its pharmaceutically acceptable non-toxic inorganic or organic salt: ##STR6## wherein A stands for --S-- or --NH-- and n is an integer of from 5 to 12.
Claim 2
Dependent Claim 35 words
A cyclic adenosine monophosphate represented by the formula, or its pharmaceutically acceptable non-toxic inorganic or organic salt: ##STR6## wherein A stands for --S-- or --NH-- and n is an integer of from 5 to 12.
Claim 3
Dependent Claim 13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2, wherein A is --S--.
Claim 4
Dependent Claim 19 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is an integer of from 5 to 8.
Claim 5
Dependent Claim 19 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is an integer of from 9 to 12.
Claim 6
Dependent Claim 13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 1 wherein A is --NH--.
Claim 7
Dependent Claim 18 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is an integer of 5 to 8.
Claim 8
Dependent Claim 18 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is an integer of 9 to 12.
Claim 9
Dependent Claim 13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 5.
Claim 10
Dependent Claim 13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 6.
Claim 11
Dependent Claim 13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 7.
Claim 12
Dependent Claim 13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 8.
Claim 13
Dependent Claim 13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 9.
Claim 14
Dependent Claim 13 words
An 8-alkylmercapto cyclic adenosine monohosphate according to claim 2 wherein n is 10.
Claim 15
Dependent Claim 13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 11.
Claim 16
Dependent Claim 13 words
An 8-alkylmercapto cyclic adenosine monophosphate according to claim 2 wherein n is 12.
Claim 17
Dependent Claim 13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 5.
Claim 18
Dependent Claim 13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 6.
Claim 19
Dependent Claim 13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 7.
Claim 20
Dependent Claim 13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 8.
Claim 21
Dependent Claim 13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 9.
Claim 22
Dependent Claim 13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 10.
Claim 23
Dependent Claim 13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 11.
Claim 24
Dependent Claim 13 words
An 8-alkylamino cyclic adenosine monophosphate according to claim 5 wherein n is 12.
Claim 25
Dependent Claim 31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 1 and a pharmaceutically acceptable carrier therefor.
Claim 26
Dependent Claim 31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 2 and a pharmaceutically acceptable carrier therefor.
Claim 27
Dependent Claim 31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 3 and a pharmaceutically acceptable carrier therefor.
Claim 28
Dependent Claim 31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 4 and a pharmaceutically acceptable carrier therefor.
Claim 29
Dependent Claim 31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 5 and a pharmaceutically acceptable carrier therefor.
Claim 30
Dependent Claim 31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 6 and a pharmaceutically acceptable carrier therefor.
Claim 31
Dependent Claim 31 words
A pharmaceutical composition comprising an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 7 and a pharmaceutically acceptable carrier therefor.
Claim 32
Dependent Claim 46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 1.
Claim 33
Dependent Claim 46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 2.
Claim 34
Dependent Claim 46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 3.
Claim 35
Dependent Claim 46 words
A method of treating diseases caused by disorder of the introcellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 4.
Claim 36
Dependent Claim 46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 5.
Claim 37
Dependent Claim 46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 6.
Claim 38
Dependent Claim 46 words
A method of treating diseases caused by disorder of the intracellular cyclic adenosine monophosphate level which comprises administering to a patient suffering from such disease an effective amount of a cyclic adenosine monophosphate or pharmaceutically acceptable non-toxic inorganic or organic salt thereof according to claim 7.

References Cited (Backward Citations)

US3712885A Cited
US3752805A Cited
US3872098A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-09-12 1981-03-14 1981-09-13 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-09-12 1985-03-14 1985-09-13 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-09-12 1989-03-14 1989-09-13 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag